Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,336.00-0.64%ETH$2,278.68-0.42%GOLD$3,925.00-1.12%OIL$97.09+0.65%
Smart Investors Daily
SID Premium
TL

NASDAQ · TLSA

Tiziana Life Sciences Ltd

Healthcare · Biotechnology

$0.67

Down-$0.13 (-16.25%)

Updated Nov 3, 2026, 12:37 PM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
95.86M
P/E ratio
-4.09
Dividend yield
0.00%
52-week range
$0.62 – $1.85
Volume
2.85M
Avg. volume
329.18K

Price performance · TLSA

TLSA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

TLSA closed at $0.67 after 21 trading sessions, down 37.38% for the selected period.

Last close
$0.67
Period change
-37.38%
Period low
$0.67
Period high
$1.19
Daily close
View OHLC price history
TLSA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.8401$0.8575$0.621$0.672.85M
Oct 30, 2026$0.897$0.9162$0.79$0.801.29M
Oct 29, 2026$0.95$0.95$0.90$0.9047187.83K
Oct 28, 2026$0.89$0.9586$0.88$0.95250.7K
Oct 27, 2026$0.88$0.9429$0.872$0.872190.53K
Oct 26, 2026$0.95$0.95$0.86$0.8823377.67K
Oct 23, 2026$0.97$0.98$0.93$0.9501252.2K
Oct 22, 2026$0.9797$1.01$0.94$1.00494K
Oct 21, 2026$1.03$1.03$0.9699$1.01421.48K
Oct 20, 2026$1.02$1.03$0.99$1.01299.45K
Oct 19, 2026$1.06$1.07$0.9905$1.01333.03K
Oct 16, 2026$1.08$1.10$1.03$1.05563.22K
Oct 15, 2026$1.05$1.07$1.02$1.05264.39K
Oct 14, 2026$1.06$1.08$1.03$1.05581.58K
Oct 13, 2026$1.09$1.12$1.05$1.09492.64K
Oct 12, 2026$1.20$1.20$1.0699$1.09567.65K
Oct 9, 2026$1.14$1.2475$1.1299$1.192.42M
Oct 8, 2026$1.11$1.15$1.105$1.13449.95K
Oct 7, 2026$1.11$1.135$1.07$1.10384.74K
Oct 6, 2026$1.08$1.135$1.05$1.11634.19K
Oct 5, 2026$1.12$1.14$1.07$1.07274.64K

Latest TLSA news

The latest Smart Investors Daily articles mentioning TLSA.

Stock researchCompany · Overview

TLSA research

Overview

Company profile and research snapshot.

Company profile

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TLSA recent ratings
DateFirmRatingTarget
Sep 22, 2026BTIGBuy—
Sep 3, 2026BTIGBuy—
Jun 13, 2022ThinkEquityBuy—
Apr 12, 2021Zacks Investment ResearchNot Rated—
Sep 21, 2020HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee f

Yahoo · Oct 16, 2026

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer’s disease (AD). Topl

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By